New Drug Approvals

APRIL 18, 2025

1 November 2022). 17 February 2022). . “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82” WHO Drug Information. hdl : 10665/330879. Further reading Auchus, Richard; Chan, Jean; Farber, Robert; Fechner, Patricia; Giri, Nagdeep; Nokoff, Natalie; et al. (1 6 (Supplement_1): A618.

FDA

New Drug Approvals

APRIL 19, 2025

21 December 2022. “Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias” Clinical Pharmacology and Therapeutics. 24 August 2022. Further reading Shiga T (June 2022). . ^ “Details for: Sibboran” Health Canada. 20 November 2023.

FDA

New Drug Approvals

JULY 18, 2025

8] It costs 350 Chinese yuan per 7 days for COVID, as of November 2022. [9] SYN [link] Azvudine was approved for the treatment of adult HIV-1 infection in China in 2021, and it was approved for conditional marketing for the treatment of SARS-CoV-2 in China in 2022. 2022, 55, 565−578. (8) 2020, 63, 8554−8566. (7) 7) Chang, J.

RNA

New Drug Approvals

JULY 28, 2025

CHINA 2022 Dorzagliatin is a glucokinase activator that is being developed to treat diabetes. [1] Drugs 2022, 82, 1745−1750. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. 2022, 37, 606−615. 133) Syed, Y.

Small Molecule

New Drug Approvals

JULY 21, 2025

Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals. China Patent CN 113929668, 2022. (51) Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. 2018, 22, 5367−5377. (48) 48) Zheng, L.; Basic Clin. 49) Mei, H.;

Small Molecule

Drug Patent Watch

DECEMBER 10, 2024

The Importance of Scientific Expertise Generic drug development involves a deep understanding of the scientific principles underlying drug development, including pharmacology, pharmacokinetics, and bioequivalence. Scientific experts in these fields are critical in ensuring that generic drugs are developed to meet the required standards.

Drug Development

ASPET

AUGUST 21, 2024

In 2022, ICH released E14/S7B Q&As (Stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds. This review details the onset mechanisms of drug-induced TdP, including I Kr inhibition, pharmacokinetic factors, autonomic regulation and reduced repolarization reserve.

Compliance

Metabolite Tales Blog

APRIL 4, 2023

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. Poster at ISSX/MDO 2022 Seattle meeting. [6] We hope it was a useful two-parter! Br J Pharmacol.

Small Molecule

New Drug Approvals

SEPTEMBER 10, 2024

Yin, Wei; Han, David; Khudyakov, Polyna; Behrje, Rhett; Posener, Joel; Laurenza, Antonio; Arkilo, Dimitrios (August 2022). “A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia” British Journal of Clinical Pharmacology.

Clinical Pharmacology

Alta Sciences

OCTOBER 15, 2024

He was promoted to Associate Director, Program Management , in 2022, and now oversees a team of program managers who guide end-to-end solutions, including preclinical , clinical , CDMO , regulatory , and bioanalytical solutions.

Pharmacokinetics

Common Sense for Drug Policy Blog

JUNE 24, 2024

The structure differs depending on the lipophilicity and steric expansion, which affects the pharmacokinetic aspects, but also the key interaction with monoamine transporters (MATs) in the central nervous system [ 112 , 113 ]. A review of synthetic cathinones emerging in recent years (2019–2022). Zawadzki, M. & Szpot, P.

Pharmacokinetics

The Premier Consulting Blog

AUGUST 8, 2024

On July 31, 2024, the US Food and Drug Administration (FDA) announced Fiscal Year 2025 (FY2025) Prescription Drug User Fee Amendments of 2022 (PDUFA VII) fee rates for the review of human drug and biological product applications along with prescription drug program fees. patients with renal, hepatic, or cardiovascular concerns).

Drugs

Drug Target Review

SEPTEMBER 25, 2024

2022 Dec 12 [cited 2024 Sep 4];22(3):213–34. A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors. References 1.Jin Jin H, Wang L, Bernards R. Nature Reviews Drug Discovery [Internet]. Available from: [link] 2.Bell

Small Molecule

The Pharma Data

APRIL 4, 2023

As part of the comprehensive submission package to the European Marketing Authorization, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50 mg/mL 2 with the 100 mg/mL (HCF). Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2

Biosimilars

New Drug Approvals

DECEMBER 24, 2023

December 2022). “Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis” British Journal of Clinical Pharmacology. 330 (15): 1448–1458. doi : 10.1001/jama.2023.18688. 2023.18688. PMC 10540057. PMID 37768671. Diep, John K.; Yu, Rosie Z.;

Clinical Trials

DrugBaron

FEBRUARY 7, 2022

Another common pitfall in medicinal chemistry is optimise one characteristic at once: find super-potent molecules, then try and ‘fix’ the pharmacokinetics and then try and improve the pharmaceutical properties and so on. A video of the whole discussion is also available on the RxCelerate Youtube channel.

Small Molecule

New Drug Approvals

SEPTEMBER 13, 2024

2] As of July 2022, it is in phase 3 clinical trials for major depressive disorder. [2] 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 2] As of July 2022, it is in phase 3 clinical trials for major depressive disorder. [2] 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1]

Treatment

The Premier Consulting Blog

JANUARY 31, 2023

On November 1, 2022, the U.S. Pharmacokinetic and systemic exposure data is also important to consider. Source: ICH S1B(R1), August 2022. 2022 Jan;35(1):53-73. The information should be relevant according to six key WoE factors: target biology, secondary pharmacology, previously conducted studies (e.g., J Toxicol Pathol.

Small Molecule

The Pharma Data

MARCH 25, 2022

Artificial intelligence is now used to map evidence and trends in traditional medicine and to screen natural products for pharmacokinetic properties. The onsite launch of the new WHO global centre for traditional medicine in Jamnagar, Gujarat, India will take place on April 21, 2022.For Source link: [link].

Government

Metabolite Tales Blog

JANUARY 23, 2024

The bigger picture An analysis of the metabolism of most commonly prescribed drugs in 2022 [2] revealed that of the 89 subject to drug metabolism, 75% were cleared via phase I mechanisms, with nearly half of these metabolised by CYP3A4. Pharmacokinetics and Metabolism of Nirmatrelvir. 2] Iversen et al., Basic Clin Pharmacol Toxicol.

Small Molecule

Drug Target Review

SEPTEMBER 19, 2023

The organoid technology recreates different disease scenarios in addition to the healthy models with age specific phenotypes and enables recreating drug specific Pharmacokinetics that is more relevant to human in vivo system.

Animal Testing

The Pharma Data

OCTOBER 27, 2020

million Series A gives it the capital to take their PRTX007 candidate into a short-term pharmacokinetic, pharmacodynamic and tolerability study, followed by a clinical proof-of-concept in an acute viral disease setting. The bladder cancer therapy is expected to be in the clinic by 2022. The company’s $27.4

Small Molecule

Practical Cheminformatics

JANUARY 8, 2024

In 2022, several papers , including one of ours , showed the promise of active learning approaches in drug discovery. In our 2022 paper , we evaluated 5 different ML models and saw minimal differences in performance. The ML model can predict the remaining molecules' free energies and prioritize the next set of free energy calculations.

Drugs

New Drug Approvals

OCTOBER 24, 2023

July 2022). . | twitter +919321316780 call whatsaapp EMAIL. “Velsipity (etrasimod) tablets, for oral use” (PDF). . “Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies” Lancet. 401 (10383): 1159–1171. PMID 36871574. ^

FDA

Vial

MARCH 15, 2024

Examples of vendors include: Laboratories : CROs often collaborate with specialized laboratories for various purposes, such as sample analysis or pharmacokinetic studies, among others. These collaborations with external vendors are aimed at accessing specialized expertise, technologies, or resources that they may not have in-house.

Clinical Trials

New Drug Approvals

JANUARY 31, 2024

citation needed ] The pharmacokinetic properties of obeldesivir and improved was first published by Chinese researchers in May 2022. References ^ “Clinical Trials Register” ^ “Gilead touts Veklury resilience against mutated coronavirus, plots phase 3 for new COVID oral antiviral” 19 October 2022. ^ Cho, A.;

RNA

Alta Sciences

APRIL 17, 2024

According to a 2022 article published in Molecular Psychiatry, treatment resistance affects 20 to 60% of patients with psychiatric disorders. In 2022, a GIP-GLP-1R coagonist, tirzepatide, used to treat people with T2D, was found to produce significant weight loss and was also approved for treatment of obesity.

Drug Development

Agency IQ

AUGUST 9, 2024

While the new version of the guidance is greatly expanded as compared to an earlier version from 2022, it has left plenty of important questions unanswered. In this piece, AgencyIQ answers some of the most common questions we’ve received about the guidance – and raise a few of our own. What happens if you don’t meet your goals?

Science

Agency IQ

DECEMBER 11, 2023

BY LAURA DIANGELO, MPH | DEC 4, 2023 2:46 PM EST Diversity in clinical research: Guidance and statute In April 2022, the FDA issued a new draft guidance document on diversity in clinical research programs. FDORA was passed into law in December 2022 as part of the end-of-year 2023 federal spending bill.

FDA

Metabolite Tales Blog

DECEMBER 13, 2023

8(2):3640-3648; [link] [11] Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality. J Pharm Biomed Anal. 22(5):803-11; [link] [10] Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas? Sundararaghavan VL, Sindhwani P, Hinds TD Jr. Oncotarget.

Small Molecule

Agency IQ

AUGUST 11, 2023

The FDA issued a draft guidance on RRAs outside of the Covid-19 PHE context in July of 2022, which stated that all RRA-associated documents should be submitted in electronic format, and even paper documents should be scanned as searchable Portable Document Format (PDF) files for submission.

FDA

The Pharma Data

APRIL 11, 2023

A focus of the presentation will be on the target engagement results and pharmacokinetics from its ongoing monotherapy dose-escalation study to explore a potential optimal dose and schedule to effectively inhibit AhR. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. billion euros.

Research

Agency IQ

SEPTEMBER 15, 2023

The committee also made recommendations regarding pharmacokinetic and safety assessments. When looking at several pharmacokinetic studies, the FDA found that the 10 mg oral dose of phenylephrine has a very low bioavailability of less than 1% and, subsequently, low systemic alpha-1 adrenergic activity. billion for pseudoephedrine.

Science

Metabolite Tales Blog

MARCH 1, 2023

2018, 26, 965-972 [link] 4a Pharmaceutics, 2022, 14, 1001 [link] 5 Phys. 2010, 75, 9, 3141–3143 [link] 22 Clin Pharmacokinet. 2017, 30, 1, 13–37 [link] 2a Drug Metab. 2006 , 34, 145-51 [link] 3 Drug Metab. 1980, 8, 34-38 [link] 4 J. Food Drug Anal. 2000, 2, 195-201 [link] 6 Biochem. 1966 98, 266-277 [link] 7 Metabolites.

Metabolic Stability

The Pharma Data

APRIL 8, 2021

We expect data from the studies in 2022. This includes the number of infants able to sit without support for 5 and 30 seconds, a key motor milestone not normally seen in the natural course of the disease, as well as data on event-free survival and reduced hospitalisations. Huntington’s Disease (HD).

Clinical Trials

The Pharma Data

NOVEMBER 4, 2020

The Company expects to report topline results from the THRIVE-AA1 trial in 2022. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy.

Pharmaceuticals

The Pharma Data

JANUARY 10, 2021

. Ascendis anticipates completion of enrollment in foresiGHt, a global phase 3 trial evaluating the safety and efficacy of lonapegsomatropin in adult patients with GHD, by late 2021 or early 2022. . . . •. ?. . . •.

Clinical Trials